Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

AI-Powered study to uncover hidden health risks in overweight chinese adults

NCT ID NCT07584330

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This 5-year study will follow 2,800 overweight or obese Chinese adults aged 18-60 to see how their health changes over time. Participants will use a smartphone app to track their data and get lifestyle support. The goal is to understand who develops diabetes or complications, and why.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could reveal patterns that help predict who is at risk for diabetes or complications, leading to earlier interventions.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly test any new therapy. Results may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,800 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Apr 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Chinese adults aged 18-60 years with overweight or obesity (BMI ≥ 24 kg/m² or central obesity: male waist circumference ≥ 90 cm, female ≥ 85 cm). Enrolled from 24 hospitals across China. Participants are classified into three groups: metabolically healthy overweight/obesity (MH-OW/OB), metabolically unhealthy overweight/obesity (MU-OW/OB), and type 2 diabetes with overweight/obesity (T2DM-OW/OB). All participants must be able to use a smartphone for daily communication and provide written informed consent. Key exclusions include type 1 diabetes, severe hepatic/renal impairment, uncontrolled hypertension or diabetes (HbA1c \> 9.0%), active malignancy, pregnancy, and conditions interfering with follow-up or AI platform use.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Able to understand and voluntarily sign the informed consent form, and willing to comply with all study requirements. 2. Age between 18 and 60 years (inclusive). 3. Meets at least one of the following overweight/obesity criteria: a) BMI ≥ 24 kg/m²; b) male waist circumference ≥ 90 cm, female waist circumference ≥ 85 cm. 4. Capable of basic smartphone operation and able to use WeChat or similar communication tools for daily communication. Exclusion Criteria: 1. Diagnosis of type 1 diabetes, latent autoimmune diabetes in adults (LADA), maturity-onset diabetes of the young (MODY), or other specific types of diabetes. 2. Endocrine or metabolic diseases that may affect body weight, including untreated thyroid disorders (hyperthyroidism: TSH \< 0.1 mIU/L with FT4 \> upper normal limit; hypothyroidism: TSH \> 10 mIU/L), Cushing syndrome, acromegaly, polycystic ovary syndrome, or hypopituitarism. 3. Severe liver disease (Child-Pugh class B or C). 4. Renal insufficiency (estimated glomerular filtration rate \< 30 mL/min/1.73 m²). 5. Severe cardiac dysfunction (New York Heart Association class III or IV). 6. Major cardiovascular or cerebrovascular event within the past 3 months (acute coronary syndrome, stroke). 7. Uncontrolled hypertension (systolic blood pressure ≥ 180 mmHg or diastolic ≥ 110 mmHg) or uncontrolled diabetes (HbA1c ≥ 9.0%). 8. Active malignancy (diagnosed or treated within the last 3 years). 9. Inflammatory bowel disease or conditions causing malabsorption (Crohn disease, active ulcerative colitis, pancreatitis with steatorrhea). 10. Neuropsychiatric disorders (anorexia nervosa, bulimia nervosa, schizophrenia, major depression, or bipolar disorder). 11. Diseases or physical conditions that impair motor function (severe osteoarthritis, Parkinson disease, paralysis, or cardiopulmonary insufficiency). 12. Long-term use of antipsychotic drugs, systemic glucocorticoids, or other medications judged by the investigator to affect study outcomes. 13. Pregnancy or planned pregnancy during the study period. 14. History of or planned organ transplantation. 15. Inability to operate the AI-based system or comply with follow-up procedures. 16. Concurrent participation in another interventional clinical trial that may influence the results of this study. 17. Unwilling or unable to provide informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus type 2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.